ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024
ZEISS Medical Technology will showcase the latest in 3D visualization technology and surgical innovation at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 5-8, 2024, in Boston, MA. Building on its ZEISS Medical Ecosystem, several of the new innovations enable seamless data…
SweetWater Brewing Launches Hammer Red Amber Ale to Support Georgia Aquarium
SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast and a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), announced today the release of its new Hammer Red Amber Ale, the latest collaboration beer as…
Get Ready to Elevate Your Chill Game with Evn’s New Hybrid Gummies!
Roll out the green carpet and get your taste buds ready for a delightful new twist in the world of hemp-derived delights—Evn’s fresh-off-the-vine Hybrid Gummies are here! The new Hybrid Gummies stand out not just for their equilibrium of cannabinoids, with a balanced 1:1…
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
Today, Ajinomoto Co., Inc. (“Ajinomoto Co.”) (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC)…
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit’s AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer…
Novel research leverages AI to identify dogs at higher risk for cancer
A novel canine cancer study funded by Morris Animal Foundation and the Golden Retriever Foundation® is leveraging artificial intelligence to pioneer an innovative approach to early detection and prevention for dogs suspectable to developing diffuse large B-cell lymphoma, the most common form of…
LifeLabs Unveils At Home Kit Program, Empowering Ontarians to Prioritize Health with Ease
LifeLabs, a leading provider of laboratory diagnostic services, is thrilled to introduce our latest offering: At-Home Self-Collection Kits. LifeLabs’ At Home Kit Program provides a diverse range of self-collection kits for various health tests, including cervical to colorectal health, hormonal…
A pioneering two-day workshop in Bangalore to understand how climate change and caste and gender discrimination can make infections harder to treat
The One Health Trust, funded by the World Health Organization and the British Academy, hosted a two-day workshop focused on developing inclusive policy recommendations for our changing world. The workshop highlighted the urgent need to address antimicrobial resistance (AMR), which…
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar…
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”) studying the company’s drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (“PDAC”). The manuscript titled “Rintatolimod in…